U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06951867) titled 'Tezspire Cardiac Events PASS' on April 23.
Brief Summary: The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for severe asthma.
Study Start Date: Sept. 15, 2025
Study Type: OBSERVATIONAL
Condition:
Cardiovascular Events
MACE
Intervention:
DRUG: Tezepelumab
The exposure of primary interest is tezepelumab for severe asthma. Exposure will be assessed based on prescriptions or administrations depending on the data source. A comparable cohort of unexposed patients tr...